A real world study for the effectivenss and safety of Nab-paclitaxel in patients with gastric cancer in Anhui Province.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800020429

Enrollment

Unknown

Registered

2018-12-29

Start date

2018-12-26

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

case series:Nab-paclitaxel ± other treatments

Eligibility

Sex/Gender

All

Age

18 Years to 8 Years

Inclusion criteria

Inclusion criteria: 1. Aged at least 18 years; 2. Gastric cancer confirmed histologically/cytologically; 3. Voluntarily participate in this study and sign the informed consent form; 4. Patients who physicians consider can benefit from the trial.

Exclusion criteria

Exclusion criteria: 1. Allergic to Nab-paclitaxel or the theauxiliary materials; 2. Pregnant or lactating female patients; 3. Contraindicated to Nab-paclitaxel; 4. Patients who physicians suggest not be included.

Design outcomes

Primary

Measure	Time frame
PFS;DFS;	—

Secondary

Measure	Time frame
OS;ORR;AE;	—

Countries

China

Contacts

Public ContactGuoping Sun

The First Affiliated Hospital of Anhui Medical University

sunguoping@ahmu.edu.cn+86 13805609309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026